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Summary: Epidemiological evidence suggests that plasma high-density lipoprotein (HDL) is protective against
coronary artery disease, whereas oxidatively modified low density lipoprotein is atherogenic. Human apolipoprotein
A-I transgenic mice with overexpression of the human apolipoprotein A-I gene have increased plasma levels
of apolipoprotein A-I and HDL-cholesterol. We analyzed LDL oxidation by determination of LDL associated
malondialdehyde, peroxides and conjugated dienes. The present study demonstrates that HDL from both normal
and human apolipoprotein A-I transgenic mice at similar concentrations inhibits LDL (protein concentration 500
mg/1) lipid peroxidation, but the effect of the human apolipoprotein A-I transgenic mice HDL was two-fold greater
than that of HDL derived from normal mice. In addition, the electrophoretic mobility of oxidatively modified LDL
was reduced about two-fold in the presence of human apolipoprotein A-I transgenic mice HDL than that obtained
in the presence of normal mice HDL. We thus suggest that human apolipoprotein A-I possesses antioxidant proper-
ties which might neutralize LDL lipid peroxidation. This may underline the mechanism responsible for the lower
prevalence of atherosclerosis in subjects with high plasma levels of HDL and apolipoprotein A-I.
Introduction which HDL might protect against the atherosclerotic
„ . , . , . , ,. , , . t . process in addition to its role in reverse cholesterolEpidemiological studies have shown an inverse relation ^_ __transport.between plasma HDL cholesterol levels and coronary
artery disease (1-4). However, the underlying mecha- Recently, the transgenic mouse model with overexpres-
nisms responsible for this protective action of HDL are sion of the human apolipoprotein A-I gene has been de-
not yet well established. The most widely accepted hy- scribed (14, 15). These animals have increased levels of
pothesis is that HDL facilitates reverse cholesterol trans- apolipoprotein A-I and HDL-cholesterol, which, in turn,
port (5-8), but other mechanisms, such as the protective may be responsible for their resistance to atherosclero-
effect of HDL on vessel wall and the possible effect sis. Rubin et al. (16) have recently demonstrated that the
of HDL on the atherogenic apolipoprotein B containing atherosclerotic lesion is significantly reduced in human
lipoproteins, may also be important (9). apolipoprotein A-I transgenic mice compared to control
littermates after 4 months on a high cholesterol diet.
Several lines of evidence suggest that LDL oxidation
contributes to atherosclerosis (8, 10, 11). Oxidatively H£>L ̂ s previously been shown to reduce the cytotoxic
modified LDL is taken up by macrophages at an *fects° i ^en incubated with endothehal cells
increased rate in comparison to native LDL, and thus, 07-20). ̂ is could be due to the protective effect of
can promote cellular cholesterol accumulation and foam HDL ̂ ^ ,the toxlc effect of the ^»V<*™ 0») or
cell formation, the hallmark of early atherosclerotic aSamst LDL hPld P^oxtdauon (20).
lesions (12, 13). Possible HDL-mediated inhibition of The present study was undertaken in order to explore
LDL oxidation may be an additional mechanism by the potential protective effect of human apolipoprotein
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A-I against HDL lipid pcroxidation by using mice HDL
derived from human apolipoprotein A-I transgenic (Hu-
AITg) mice.
Methods
Human apolipoprotein A-l transgenic mice were kindly provided
to us by Dr. Jan Breslow, The Rockefeller University, New York,
U. S. A. Transgenic mice expressing the human apolipoprotein Α-
Ι gene have increased plasma levels of human apolipoprotein A-I
and HDL cholesterol (14, 15). Blood was collected from the retro-
orbital plexus under anesthesia with ether (14, 21) into Eppendorf
tubes with 1 mmol/1 Na?EDTA. Lipoproteins (VLDL, d < 1.006
kg/1; LDL, d = 1.006-1.063 kg/1; HDL, d = 1.063-1.210 kg/1)
were isolated from 3 ml of pooled plasma from human apolipopro-
tein A-l transgenic mice or from control littermates by sequential
ultracentrifugation as previously described (14, 21). Human LDL
was isolated from healthy volunteers' plasma by the same method.
The isolated lipoproteins were dialyzed against 150 mmol/1 NaCl,
l mmol/1 EDTA, pH 7.4. Plasma cholesterol in lipoproteins was
determined by enzymatic methods (14). Human apolipoprotein Α-
Ι levels were measured by a turbidimetric immunoassay applied
for semiautomatic analyzer (22) and protein was measured by the
method of Lowry et al. (23).
Plasma concentration of human apolipoprotein A-I in a represen-
tative group of human apolipoprotein A-I transgenic mice was
2800 ± 300 mg/1 compared to mouse apolipoprotein A-I levels
of 1500 ±200 mg/1 in normal littermates, and plasma HDL
cholesterol concentration was 880 ± 30 mg/1, compared to HDL-
cholesterol of 490 ± 30 mg/1 (n = 8) in controls. It was pre-
viously shown (24, 25) that, in human apolipoprotein A-I
transgenic mice, the major plasma apolipoprotein is human apoli-
poprotein A-l and their HDL pattern is human-like with both
HDL2 and HDL3 subtractions (in normal mice only o.ne HDL
fraction, which is HDL2, exists).
LDL oxidation was induced after an overnight dialysis of the lipo-
protein against EDTA-free phosphate buffered saline. The lipopro-
teins were then diluted with phosphate buffered saline to a final
protein concentration of 0.5 gA. In order to compare the effect of
HDL derived from human apolipoprotein A-I transgenic mice to
that of control HDL derived from normal mice on LDL oxidation,
human LDL (protein concentration 1500 mg/l) was incubated with
control HDL or with human apolipoprotein A-I transgenic mice
HDL (protein concentration 0.5 g/1) in the presence of 10 μιηοΐ/ΐ
CuSO4 for 3 h at 37 °C. Lipoprotein oxidation was terminated by
refrigeration and the addition of 1 mmol/1 Na2 EDTA. The oxida-
tive state of the lipoproteins was assayed by determination of the
thiobarbituric acid reactive substance assay (26), the content of
conjugated dienes at 234 nm (27) and lipid peroxide formation
using a commercially available kit (CHOD iodide method, Diag-
nostic® Merck, Darmstadt, Germany) based on the ability of lipid
peroxides to convent iodide to iodine (28). Similar analyses were
performed on lipoproteins that were incubated under non-oxidative
stress (in the absence of CuSO4). In addition, the lag time and the
kinetics of LDL and HDL oxidation was determined by monitoring
the changes measured at 234 nm in absorbance, observed at room
temperature (23 °C) of freshly isolated human LDL (protein con-
centration 200 mg/1 of phosphate buffered saline), control mouse
HDL (protein concentration 200 mg/1), human apolipoprotein A-I
transgenic mice HDL (protein concentration 200 mg/1), mixtures
of human LDL and control mouse HDL or human LDL and human
apolipoprotein A-I transgenic mouse HDL in the concentrations
indicated above, following incubation with CuSO4 (10 μηιοΐ/ΐ). Ab-
sorbance was recorded every 10 minutes for a period of 3 hours.
The effect of HDL from human apolipoprotein A-I transgenic mice
or from control littermates on human LDL oxidation was also as-
sessed by agarose gel electrophoresis. This was carried out on 0.7%
agarose gels at pH 8.6 in 0.05 mol/1 barbital buffer (29), and the
electrophoretic mobility of oxidized LDL under the various experi-
mental conditions was measured.
Results
The susceptibility of human LDL (pfrotein concentration
500 mg/1) to undergo lipid peroxidation under oxidative
stress (10 μιηοΐ/ΐ CuSO4) was analyzed in the presence
of HDL (protein concentration 500 mg/1) derived from
normal or from human apolipoprotein A-I transgenic
mice.
Both human LDL and HDL from normal mice were
oxidized when incubated with 10 μιηοΐ/ΐ CuSO4 for
3 h at 37 °C (fig. 1). The susceptibility of human LDL
to lipid peroxidation was considerably higher than that
of the HDL from the normal mice with 2-fold increase
in malondialdehyde levels, 11-fold increase in the per-
oxide content and 4-fold increase in LDL conjugated
dienes content (fig. la-c). We then tested the effect
of HDL from the control mice on the oxidizability of
human LDL. The measured lipid peroxidation rate of
human LDL that was incubated together with HDL
from the normal mice was 25%, 22% and 28% lower
for malondialdehyde, peroxide and conjugated dienes,
respectively, than the expected oxidation, calculated
by adding LDL and HDL lipid peroxidation rates
(fig. la-c).
We next studied the effect of HDL from human apolipo-
protein A-I transgenic mice on human LDL suscep-
tibility to lipid peroxidation. The lipid peroxidation rate
. of HDL from human apolipoprotein A-I transgenic mice
was significantly higher (p < 0.01) than that of normal
mice HDL (see fig. 2, HDL vs fig. 1, HDL). The effect
of HDL from human apolipoprotein A-I transgenic mice
on human LDL susceptibility to lipid peroxidation was
then analyzed. The measured lipid peroxidation of hu-
man LDL when incubated together with HDL from hu-
man apolipoprotein A-I transgenic mice was 51%, 34%
and 54% lower than the expected lipid peroxidation as
calculated by adding the lipoprotein lipid peroxidation
rates for malondialdehyde, peroxide and conjugated
dienes, respectively (fig. 2a—c). These results demon-
strate that HDL from human apolipoprotein A-I
transgenic mice inhibits human LDL lipid peroxidation
by about 50%, a 2-fold higher inhibitory effect on hu-
man LDL oxidation in comparison to the effect of HDL
from normal mice. Kinetic analysis of Cu24" induced
LDL oxidation revealed similar results, suggesting that
both human apolipoprotein A-I transgenic and control
mouse HDL not only attenuate the maximal final level
of LDL oxidation but also delay the oxidative process
of LDL.
The lag time for human LDL oxidation was 48 minutes,
whereas, upon incubation of the human LDL with con-
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trol HDL as well as with human apolipoprotein A-I
transgenic mice HDL, the lag time was significantly de-
creased to 35 and 34 minutes, respectively, again indi-
cating the inhibitory effect of both HDL preparations on
LDL oxidation. Of special interest was the finding that,
whereas the lag time of the oxidation of control HDL
was 46 minutes, on using human apolipoprotein A-I
transgenic mice HDL, the lag time was as short as 25
minutes. This latter result suggests that human apolipo-
protein A-I transgenic mouse HDL is a more potent anti-
oxidant than control mouse HDL which can be attrib-
uted to its higher capacity to undergo lipid peroxidation.
A similar pattern was found on calculating the slope of
the propagation phase of LDL oxidation (data not
shown).
LDL lipid peroxidation is associated with increased
electrophoretic mobility. The electrophoretic mobility of
human LDL (protein concentration 500 mg/1) was mea-
sured following its incubation with HDL (protein con-
centration 500 mg/1) derived from normal mice or from
human apolipoprotein A-I transgenic mice in the ab-
sence or presence of 10 μπιοΐ/ΐ CuSO4 for 3 h at 37 °C
(tab. 1). LDL lipid peroxidation in the presence of cop-
per ions increased the electrophoretic mobility of native













LDL HDL LDL+HDL LDL+HDL
(calculated) (measured)
Fig. 1 The susceptibility of human LDL to lipid peroxidation in
the presence of HDL from normal mice under oxidative stress (10
umol/1 CuSO4). Lipoprotein oxidation was carried out by incuba-
tion for 3 h at 37 °C followed by analysis of malondialdehyde (a),
peroxides (b) and conjugated dienes (c). Note that the results for
LDL and HDL alone are expressed as nmol per 0.5 mg lipoprotein
protein whereas, for both measured and calculated lipid peroxida-
tion of LDL + HDL, the results represent nmol per 1.0 mg lipopro·?
tein protein., The results are expressed as mean ± SE of 3 different
experiments. * p < 0.01 (LDL + HDL measured oxidation vs LDL
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Fig. 2 The susceptibility of human LDL to lipid peroxidation in
the presence of HDL from human apolipoprotein A-I transgenic
mice under oxidative stress (10 μιηοΙ/1 CuSO4). Lipoprotein oxida-
tion was carried out by incubation for 3 h at 37 °C followed by
analysis of malondialdehyde (a), peroxides (b) and conjugated
dienes (c). Note that the results for LDL and HDL alone are ex-
pressed as nmol per 0.5 mg liprotein protein whereas, for both
measured and calculated lipid peroxidation of LDL + HDL, the
results represent nmol per 1.0 mg lipoprotein protein. The results
are expressed as mean ± SE of 3 different experiments. * p < 0.01
(LDL + HDL measured oxidation vs LDL + HDL calculated oxi-
dation)
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Tab. 1 Effect of HDL from human apolipoprotein A-I transgenic



















































The electrophoretic mobility of human LDL (protein concentration
500 mg/1) with or without oxidative stress (10 μηιοί CuSO4) (a, b)
in the presence or the absence of HDL derived from normal (c, d)
or from human apolipoprotein A-I transgenic mice (e, f). Results
are expressed as mean ± SE of 3 different experiments.
normal mice, the electrophoretic migration of the oxi-
dized LDL was reduced by only 11% in comparison to
oxidized LDL alone (tab. lb,d). The addition of HDL
from human apolipoprotein A-I transgenic mice (tab. If)
further inhibited the migration of human LDL up to 19%
in comparison to oxidized LDL (tabl. Ib). In the absence
of copper ions, no effect of either HDL preparation
could be found.
Discussion
Several lines of evidence suggest that plasma HDL
levels inversely correlate with coronary artery disease
(1-4). The exact mechanism by which HDL protects
against atherosclerosis, however, is not known. The in-
hibitory effect of human apolipoprotein A-I on LDL oxi-
dation may suggest an additional mechanism whereby
HDL might attenuate the atherosclerotic process in addi-
tion to its well accepted role in reverse cholesterol trans-
port (5-8).
Our study demonstrates that HDL from either normal or
human apolipoprotein A-I transgenic mice inhibits LDL
lipid peroxidation, but the effect of human apolipopro-
tein A-I transgenic mice HDL was substantially greater
than that of HDL derived from normal mice, suggesting
that human apolipoprotein A-I possesses additional anti-
oxidative characteristics.
Matsuda et al. (30) have demonstrated that lipoproteins
containing only apolipoprotein A-I (LP Α-Γ) as well as
lipoproteins containing both apolipoprotein A-I and
apolipoprotein A-II (LP A-I + A-II) are capable of in-
hibiting LDL oxidation in vitro, but LP A-I was shown
to be more effective than LP A-I + A-II. This in vitro
model raises the possibility that LP A-I may play a role
in protecting LDL from copper ion-mediated oxidation,
as demonstrated in the present study. LP A-I might act
by more effectively preventing interaction of apolipo-
protein B with the malondialdehyde formed during the
oxidation process than LP A-I + A-II.
Furthermore, Klimov et al. have alscj demonstrated (20)
that HDL possesses antioxidant properties against LDL
oxidation in vitro. When HDL3 was administrered intra-
venously to hypercholesterolaemic rabbits, a decreased
ex vivo LDL lipid peroxidation was demonstrated (31),
suggesting that HDL, in addition to other antioxidative
systems, may take part in the protection of LDL from
lipid peroxidation. Klimov et al. demonstrated that
HDL3, but not HDL2, inhibits LDL oxidation in vivo
and in vitro (28, 31). In our study we used human apoli-
poprotein A-I transgenic mice HDL in which the HDL
pattern is human-like with HDL2 and HDL3 subtrac-
tions, compared to HDL from normal mice in which the
HDL comprises just one component which approximates
HDL2 in size. This may explain the higher capacity of
human apolipoprotein A-I transgenic HDL (which con-
tains both HPL2 and HDL3) to inhibit LDL oxidation
than HDL from the normal mice.
Breslow et al. recently demonstrated (9) that by cross
breeding human apolipoprotein A-I transgenic mice
with apolipoprotein Ε-deficient mice, the plasma HDL
cholesterol levels were elevated by 2-fold in compari-
son to apolipoprotein Ε-deficient mice HDL-choles-
terol and atherosclerotic lesions were significantly less
pronounced (9). Rubin et al. (32) also demonstrated
that the apolipoprotein A-I transgene corrects apolipo-
protein E deficiency-induced atherosclerosis in mice.
This latter effect may involve HDL-mediating prosta-
glandin transport (33), as well as the inhibitory effect
of apolipoprotein A-I on LDL lipid peroxidation in
the arterial wall.
Interestingly, our study demonstrates that the lipid per-
oxidation of human apolipoprotein A-I transgenic mice
HDL is considerably greater than that of normal mice
HDL. This higher propensity of human apolipoprotein
A-I transgenic mice HDL for oxidation may be related
to the mechanism by which human apolipoprotein Α-
Ι in human apolipoprotein A-I transgenic mice HDL
protects against lipid peroxidation of human LDL.
Parthasarathy et al. also suggested that HDL may play
a protective role in atherogenesis by preventing the gen-
eration of oxidatively modified LDL (34) by a mecha-
nism which involves the exchange of lipid peroxidation
products between the LDL and HDL. This mechanism
may also operate with apolipoprotein A-I in HDL from
human apolipoprotein A-I transgenic mice as demon-
strated by its higher oxidizability ίη comparison to that
of normal mice. . r
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In conclusion, the present study demonstrated that hu-
man apolipoprotein A-I possesses significant antioxida-
tive properties against LDL lipid peroxidation, and this
may underline the mechanism responsible for the pro-
tective effect observed in subjects with increased plasma
concentrations of apolipoprotein A-I (4).
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